Pre-Open Stock Movers:

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) 69.2% HIGHER; Johnson & Johnson (NYSE: JNJ) today announced it has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a company that discovers and develops novel therapies for immune-mediated diseases, in an all cash transaction for approximately $6.5 billion. Johnson & Johnson will pay $52.50 per share.

Hudson (NYSE: HUD) 48.2% HIGHER; entered into a definitive agreement with Dufry AG Group (Dufry), its controlling shareholder with 57.4% ownership of the Company, pursuant to which Dufry would acquire all of the equity interests in Hudson that it does not already own for $7.70 in cash for each Hudson Class A share (the Transaction). The per-share price represents a 50.1% premium to Hudsons closing price as of August 18, 2020, the day prior to the public announcement of the Transaction. Upon completion of the Transaction, Hudson will become an indirect wholly owned subsidiary of Dufry and will be delisted from the New York Stock Exchange.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) 27.6% LOWER; announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to the Company's Biologics License Application (BLA) for valoctocogene roxaparvovec gene therapy for severe hemophilia A on August 18, 2020. The FDA issues a CRL to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form.

Galapagos (Nasdaq: GLPG) 27.7% LOWER; announces today that Gilead Sciences, Inc. (Nasdaq: GILD) received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA). The FDA issues CRLs to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form. Gilead is the market authorization holder for filgotinib in the United States and is responsible for potential commercialization in the U.S.

Immunovant (NASDAQ: IMVT) 18% HIGHER; positive read-through to related to news Johnson & Johnson (NYSE: JNJ) may have underpaid for Momenta Phama (NASDAQ: MNTA) by paying $52.50 per share.

Vipshop Holdings (NYSE: VIPS) 15.2% LOWER; reported Q2 EPS of $0.27, $0.01 worse than the analyst estimate of $0.28. Revenue for the quarter came in at $3.4 billion versus the consensus estimate of $3.42 billion.

Accelerate Diagnostics, Inc. (NASDAQ: AXDX) 12.8% HIGHER; The company and BioCheck, Inc., a privately-held San Francisco-based company focused on in vitro diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully-automated MS-Fast instrument.

Sabre Corporation (Nasdaq: SABR) 10% LOWER; announced registered public offerings of (1) $250,000,000 of mandatory convertible preferred stock (or $287,500,000 if the underwriters fully exercise their overallotment option to purchase additional shares) and (2) $250,000,000 of common stock (or $287,500,000 if the underwriters fully exercise their option to purchase additional shares). The precise timing, size and terms of the offerings are subject to market conditions and other factors. The net proceeds from the Offerings will be used for general corporate purposes. The completion of each Offering is not contingent on the consummation of the other Offering.

Sangamo Therapeutics (NASDAQ: SGMO) 8.5% HIGHER; gains on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) CRL for valoctocogene roxaparvovec gene therapy for severe hemophilia A.

Jack Henry (NASDAQ: JKHY) 8% LOWER; reported Q4 EPS of $0.80, $0.02 better than the analyst estimate of $0.78. Revenue for the quarter came in at $410.54 million versus the consensus estimate of $413.1 million. Jack Henry sees FY2021 EPS of $3.70-$3.75, versus the consensus of $3.84. Jack Henry sees FY2021 revenue of $1.75-1.77 billion, versus the consensus of $1.7 billion.

Target (NYSE: TGT) 8% HIGHER; reported Q2 EPS of $3.38, $1.76 better than the analyst estimate of $1.62. Revenue for the quarter came in at $22.98 billion versus the consensus estimate of $20.09 billion.

Albireo Pharma, Inc. (Nasdaq: ALBO) 7.4% LOWER; announced topline results from the Phase 2 proof- of-concept clinical trial evaluating elobixibat, its ileal bile acid transporter (IBAT) inhibitor currently approved in Japan for chronic constipation, for the treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Following promising results in preclinical studies, the Phase 2 study achieved the primary endpoint of reduction of low-density lipoprotein cholesterol (LDL-C) but did not achieve proof-of-concept for other key NASH measures.

Cellectis (NASDAQ: CLLS) 6% HIGHER; Citi analyst Yigal Nochomovitz upgraded from Buy to Buy with a price target of $32.00 (from $15.00).

Sorrento Therapeutics (NASDAQ: SRNE) 6% LOWER; disclosed that on August 17, 2020, Jiong Shaos employment with Sorrento Therapeutics, Inc. terminated in its entirety, effective immediately. Mr. Shao previously served as the Companys Executive Vice President and Chief Financial Officer.

TJX Cos. (NYSE: TJX) 5.5% LOWER; reported Q2 EPS of ($0.18), $0.08 worse than the analyst estimate of ($0.10). Revenue for the quarter came in at $6.7 billion versus the consensus estimate of $6.57 billion.

Plymouth Industrial REIT, Inc. (NYSE: PLYM) 5.3% LOWER; announced that it intends to offer, subject to market and other conditions, 5,750,000 shares of its common stock. Plymouth intends to grant the underwriters a 30-day option to purchase up to an additional 862,500 shares of its common stock. Plymouth intends to use the net proceeds from this offering to fund acquisitions, including certain industrial properties under contract, and for working capital and other general purposes, including to repay outstanding indebtedness under its revolving credit facility.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX) 4.4% HIGHER; reported early interim data from the registrational Phase 2 TRIDENT-1 study of lead drug candidate, repotrectinib, and announced recent regulatory feedback from the Food and Drug Administration (FDA) on the TRIDENT-1 trial design.

Gilead Sciences, Inc. (Nasdaq: GILD) 4.4% LOWER; Galapagos (Nasdaq: GLPG) announces today that Gilead Sciences, Inc. (Nasdaq: GILD) received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis (RA). The FDA issues CRLs to indicate that the review cycle for an application is complete and that the application is not ready for approval in its present form. Gilead is the market authorization holder for filgotinib in the United States and is responsible for potential commercialization in the U.S.

Genocea Biosciences (NASDAQ: GNCA) 4% LOWER; files to offer up to 21,390,902 shares of common stock and up to 45,835,978 shares of Common Stock upon the exercise of warrants by the selling stockholders identified in this prospectus.

La-Z-Boy (NYSE: LZB) 2.6% LOWER; reported Q1 EPS of $0.18, $0.31 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $285.5 million versus the consensus estimate of $289.74 million.

Conduent Incorporated (NASDAQ: CNDT) 2.6% HIGHER; disclosed that the board of directors elected Hunter Gary, Senior Managing Director of Icahn Enterprises, L.P., to the Board. Mr. Gary is a director designated by Carl C. Icahn and certain other parties pursuant to the letter agreement, dated as of January 28, 2016, entered into by Xerox Corporation, our former parent company, with Icahn Partners Master Fund LP, Icahn Partners LP, Icahn Onshore LP, Icahn Offshore LP, Icahn Capital LP, IPH GP LLC, Icahn Enterprises Holdings L.P., Icahn Enterprises G.P. Inc., Beckton Corp., High River Limited Partnership, Hopper Investments LLC, Barberry Corp., Jonathan Christodoro and Carl C. Icahn (collectively, the “Icahn Group”). On December 31, 2016, the Company entered into a Joinder Agreement to the Icahn Agreement. Mr. Gary was also appointed to the Compensation Committee.